Analysis of Prognostic Factors in Pancreatic Metastases: A Multicenter Retrospective Analysis
Autor: | Toshihiko Matsumoto, Etsuji Ishida, Yoshinobu Okabe, Akio Yanagisawa, Hideyuki Shiomi, Shujiro Yazumi, Hironari Kato, Toshiro Katayama, Shinichi Hashimoto, Ryoji Takada, Daisuke Masuda, Motoyuki Tsuda, Takashi Ito, Hirofumi Kawamoto, Shunsuke Omoto, Keiichi Hatamaru, Ichiro Moriyama, Kiyohito Tanaka |
---|---|
Rok vydání: | 2018 |
Předmět: |
Oncology
Adult Male medicine.medical_specialty Lung Neoplasms Endocrinology Diabetes and Metabolism Kaplan-Meier Estimate Metastasis 03 medical and health sciences Young Adult 0302 clinical medicine Endocrinology Japan Internal medicine Internal Medicine medicine Humans Lung cancer Survival rate Carcinoma Renal Cell Aged Retrospective Studies Aged 80 and over Hepatology Proportional hazards model business.industry Incidence Hazard ratio Retrospective cohort study Sarcoma Middle Aged medicine.disease Prognosis Primary tumor Kidney Neoplasms Pancreatic Neoplasms 030220 oncology & carcinogenesis 030211 gastroenterology & hepatology Female business Colorectal Neoplasms |
Zdroj: | Pancreas. 47(8) |
ISSN: | 1536-4828 |
Popis: | OBJECTIVES Pancreatic metastases (PMs) account for 1% to 2% of pancreatic tumors, and their prognostic significance is poorly defined. We evaluated the incidence and clinical characteristics of primary tumors and defined prognostic factors. METHODS This retrospective study of 39 Japanese tertiary referral hospitals (January 2005 to August 2015) analyzed patient and tumor characteristics and survival time. Kaplan-Meier analysis and Cox proportional hazards models were applied to evaluate overall survival and prognostic factors, respectively. RESULTS We enrolled 159 patients with a pathologic diagnosis of PM. The most common primary tumor was renal cell carcinoma (38.4%), followed by lung cancer (24.5%), colorectal cancer (11.3%), and sarcoma (6.3%). Eight patients were lost during follow-up, and 151 patients were included for statistical analysis. Median overall survival was 43.0 months, and the 5-year survival rate was 42.6%. Multivariate analysis identified 3 independent prognostic factors: extrapancreatic metastasis (hazard ratio, 2.13; 95% confidence interval, 1.11-4.07; P = 0.02), tumor-related symptoms at diagnosis (hazard ratio, 5.39; 95% confidence interval, 2.92-9.91; P < 0.001), and pathologic diagnosis of primary tumors (P < 0.001). CONCLUSIONS Treatment strategies and prognoses for PMs completely differ according to the primary tumor type. A definitive pathologic diagnosis of PMs is essential for selecting the appropriate treatment. |
Databáze: | OpenAIRE |
Externí odkaz: |